Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

PHILIS-TSIMIKAS A., DEL PRATO S., Satman I., BHARGAVA A., DHARMALINGAM M., SKJOTH T. V., ...Daha Fazla

DIABETES OBESITY & METABOLISM, cilt.15, sa.8, ss.760-766, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 8
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1111/dom.12115
  • Dergi Adı: DIABETES OBESITY & METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.760-766
  • Anahtar Kelimeler: efficacy, insulin degludec, safety, sitagliptin, type 2 diabetes, LONGACTING BASAL INSULIN, GLYCEMIC CONTROL, OPEN-LABEL, EUROPEAN ASSOCIATION, BOLUS TREATMENT, GLARGINE, HYPOGLYCEMIA, STATEMENT, HYPERGLYCEMIA, MANAGEMENT
  • İstanbul Üniversitesi Adresli: Evet

Özet

Aim: The efficacy and safety of insulin degludec (IDeg), a new basal insulin with an ultra-long duration of action, was compared to sitagliptin (Sita) in a 26-week, open-label trial.